BY Christopher Karlsson
-
Researchers struggle to see next step for Novo Nordisk after new Alzheimer’s data
Extra information from Novo Nordisk’s 2 fell short Alzheimer’s researches have actually not raised self-confidence amongst scientists in the energetic component semaglu…
-
Advisors on Novo Nordisk’s amendment of severance agreements: It’s all about reputation
Novo Nordisk has actually chosen to alter the severance arrangements for workers that were given up throughout the significant round of redundancies in the loss.
-
Eisai and Biogen apply for new variant of Alzheimer’s drug in Japan
Leqembi, based on the active ingredient lecanemab, is already approved as an injection treatment in the US, while the drug is also approved in several countries as an intravenous t…
-
FDA extends review period for Ascendis Pharma’s dwarfism drug
According to the pharmaceutical firm, the expansion resulted from the truth that the firm sent added info to the FDA in very early November as component of the application procedur…
-
Novo Nordisk applies for higher dose of semaglutide in the US
The pharmaceutical firm anticipates a choice to take one to 2 months as soon as the FDA has actually approved the application.
-
Union Therapeutics CFO steps down
Rasmus Toft-Kehler is currently taking control of as CFO, according to Union Rehabs’ CHIEF EXECUTIVE OFFICER.
-
Novo Nordisk on the future of Alzheimer’s after disappointment: “Too early to say”
The Danish pharmaceutical firm hesitates to reveal its future prepare for Alzheimer’s after terminating 2 stage III tests on Monday.
-
Novo Nordisk’s amycretin shows weight loss of up to 14.5%
Following year, the business intends to begin stage 3 tests with amycretin in grownups with kind 2 diabetic issues.
-
Lundbeck considers next move in bidding war for Irish acquisition target
The Danish pharmaceutical firm likewise highlights that “outside chances” are a main component of the firm’s technique.
-
PensionDanmark will vote in favor of new Novo Nordisk board
Nonetheless, the firm thinks that the procedure leading up to Friday’s basic conference at Novo Nordisk has actually triggered some worry in regard to excellent company admin…
